Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses an analysis of RAS mutations in the phase III study 20050181, which compared panitumumab plus FOLFIRI versus FOLFIRI for second-line treatment of metastatic colorectal cancer.
Watch
The Efficacy of AGS-003 in mRCC
March 13th 2014Robert Figlin, MD, FACP, professor of medicine and biomedical sciences, Steven Spielberg Family Chair in Hematology Oncology, Cedars-Sinai Medical Center, discusses results from a single-arm phase II trial of the autologous dendritic cell immunotherapy AGS-003 plus standard treatment for patients with newly-diagnosed metastatic renal cell carcinoma
Watch
The Results of the RAINBOW Trial
March 12th 2014Smitha Krishnamurthi, MD, a medical oncologist and associate professor of medicine at University Hospitals Case Medical Center and Case Western Reserve University, discusses the results of the phase III RAINBOW trial, which explored ramucirumab plus paclitaxel as a second-line treatment in gastric cancer.
Watch
Sunitinib in Combination With Temsirolimus for mRCC
March 8th 2014Nizar M. Tannir, MD, FACP, associate professor, deputy department chair, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses a phase I trial of sunitinib and temsirolimus in patients with metastatic renal cell carcinoma.
Watch
Embolization Versus Embolization Plus Systemic Therapy in HCC
March 5th 2014Ghassan K. Abou-Alfa, MD, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, discusses a retrospective analysis that evaluated embolization versus embolization plus systemic therapy in patients with hepatocellular carcinoma and metastatic disease.
Watch
Validating the Link Between Obesity and Breast Inflammation in Women with Breast Cancer
February 19th 2014Neil M. Iyengar, MD, Fellow, Medical Oncology and Hematology, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses a study presented at the 2013 San Antonio Breast Cancer Symposium that further validated the link between obesity and breast inflammation in women with breast cancer.
Watch
The Benefit of Radiotherapy/Antiandrogen Combination in Men With Locally Advanced Prostate Cancer
February 18th 2014Sophie D. Fosså, MD, PhD, professor, Department of Oncology, Oslo University Hospital, Norway, comments on the benefit of radiotherapy/antiandrogen combination in men with locally advanced prostate cancer.
Watch
Revlimid Plus Dexamethasone Versus Standard Treatment for Multiple Myeloma
February 13th 2014Brian G.M. Durie, MD, chairman, International Myeloma Foundation (IMF), hematologist/oncologist, Cedars-Sinai Medical Center, Los Angeles, California, discusses results from a phase III trial that compared lenalidomide (Revlimid) plus dexamethasone versus the standard treatment of melphalan plus prednisone and thalidomide (MPT) in patients with multiple myeloma who are over 65 years old. Durie offers his thoughts regarding the impact of this trial.
Watch
An Overview of ABT-199 for the Treatment of CLL
February 12th 2014Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses the Bcl-2 inhibitor ABT-199 for the treatment of patients with CLL.
Watch